Challenges of targeting Aβ fibrillogenesis and other protein folding disorders

Amyloid

Volumn 10, Issue 3, 2003, Pages 133-135

  LeVine III, Harry ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 PROPANEDISULFONIC ACID; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID FIBRIL INHIBITOR; AMYLOID PRECURSOR PROTEIN; ANTIBODY; BETA PEPTIDE ANTIBODY; BETA SECRETASE; GAMMA SECRETASE; HOMOTAURINE; PROTEIN INHIBITOR; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOIDOSIS; CLINICAL TRIAL; DRUG EFFECT; EDITORIAL; ENCEPHALITIS; HUMAN; NONHUMAN; PASSIVE IMMUNIZATION; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN FOLDING; PROTEIN TARGETING;

EID: 0242456048     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.3109/13506120308998993     Document Type: Editorial

References (6)

1. Kirkitadze MD, Bitan G and Teplow, DB (2002). Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: The emerging role of oligomeric assemblies. J. Neurosci. Res. 69, 567-577
2. Selkoe DJ and Schenk D (2003). Alzheimer's disease: Molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43, 545-84
3. Schenk D (2002). Amyloid-β-immunotherapy for Alzheimer's disease: the end of the beginning. Nature Reviews Neuroscience 3, 824-828
4. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW and Glabe CG (2003). Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489
5. Hammarstrom P, Wiseman RL, Powers ET and Kelly JW (2003). Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 299, 713-716
6. Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP and Hawkins PN (2002). Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417, 254-259